Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the observed reduction in liver fat content (6.2%) in the GLP-1RA arm is similar to previous studies in people with MASLD,23,24”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [150]
In the citing paper
“Liraglutide promoted weight loss and beneficially altered the fat distribution by decreasing waist circumference, waist/hip ratio, and the amount of subcutaneous and visceral fat content and liver steatosis [145,150,152,155].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 acts through several distinct mechanisms including stimulation of glucose-dependent insulin secretion, inhibition of glucagon secretion, delay of gastric emptying and promotion of weight loss through central inhibition of appetite [1].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“A further possibility, consistent with the correlation we observed between effects on IHL and HBA1c, is that the effects on IHL are secondary to improved glucose tolerance, with reduced hyperinsulinemia (and perhaps reduced hyperglycaemia), reducing the increased rate of hepatocyte lipogenesis characteristic of these…”
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“NAFLD describes a disease spectrum with excessive deposition of fat within the liver (hepatic steatosis), which may be associated with inflammation, cell death, and fibrosis (non-alcoholic steatohepatitis, NASH), ultimately progressing to cirrhosis [3].”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 13×
“Reproducibility of MRI and MRS Analysis Volumetric analysis of adipose tissue content: the mean coefficient of variations (CoV) were determined as total body fat, 1–2%; total subcutaneous fat, 3–4%; abdominal subcutaneous fat, 1–3%; visceral fat, 6–8%.”
MethodInfluentialBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“dietary intervention consisting of a 600 kcal diet, liver fat reduced by a total of 7065% [35].”
BackgroundPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691 · cited 1×
“Treatment with metformin or glitazone (either rosiglitazone or pioglitazone) may also ameliorate NAFLD, with metabolic and histological improvement, predominantly through reduced steatosis and inflammation, with little effect on fibrosis [22–25].”
BackgroundMeasurement of intracellular triglyceride stores by H spectroscopy: validation in vivo
Szczepaniak, L. S., Babcock, E. E., Schick, F., Dobbins, R. L., Garg, A., Burns, D. K., McGarry, J. D., & Stein, D. T. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e977 · Cited by 688 · cited 1×
“Fat quantification by H MRS has been validated against gold standard biochemical measurements [32].”
Method
Research works printed but not linked: 1
- Centre for Clinical Practice at NICE (UK) (2009) Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. London: National Institute for Health and Clinical Excellence (UK). 22220323
Cited by
Items 101–200 of 226
Promising therapies for treatment of nonalcoholic steatohepatitis
Noureddin, M., Zhang, A., & Loomba, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220533 · Cited by 37
Trovato, F. M., Catalano, D., Musumeci, G., & Trovato, G. M. (2014) · The EPMA Journal · doi:10.1186/1878-5085-5-21 · Cited by 39
“atic steatosis and hepatic markers, such as elevated liver enzymes, and other cardiovascular risk factors [124-126].”
BackgroundBozzetto, L., Annuzzi, G., Ragucci, M., Donato, O. D., Pepa, G. D., Corte, G. D., Griffo, E., Anniballi, G., Giacco, A., Mancini, M., et al. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.011 · Cited by 34
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., Rao, A. K., Wang, R. X., Schafer, M., Pearce, M. E., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120419 · Cited by 50
Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
Gastaldelli, A., & Marchesini, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.031 · Cited by 38
“Very few studies have evaluated the hepatic effect of GLP-1RA in patients with NAFLD/NASH, in limited cohorts [9–12]; they reported a decrease in body weight and hepatic fat and a trend towards improvement in hepatic fibrosis.”
BackgroundGlucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33
Moolla, A., Poolman, T., Othonos, N., Dong, J., Smith, K., Cornfield, T., White, S., Ray, D. W., Mouchti, S., Mózes, F. E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101363 · Cited by 33
“%) in the GLP-1RA arm is similar to previous studies in people with MASLD, 23,24 although this is not a consistent fi nding in all studies.”
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 42
“…demonstrated that GLP-1RAs have a beneficial effect in patients with NAFLD, mainly in those with concomitant T2DM [50, 51, 102, 136, 148, 151, 157, 169– 195] ( Table Due to the clinical effects of GLP-1RAs, a number of studies have tried to compare them with other agents used in NAFLD treatment.”
BackgroundLiu, Y., Huang, Z., Wang, L., Liu, X., Wang, Y.-M., Zhang, Y., & Zhang, M. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.007 · Cited by 38
DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
Sugimoto, T. (2014) · Medical Science Monitor · doi:10.12659/msm.890989 · Cited by 35
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 36
Watanabe, T., Tamura, Y., Kakehi, S., Funayama, T., Gastaldelli, A., Takeno, K., Kawaguchi, M., Yamamoto, R., Sato, F., Ikeda, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12262 · Cited by 31
Management of fatty liver disease with the metabolic syndrome
Machado, M. V., & Cortez‐Pinto, H. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.903798 · Cited by 33
“Small human trials showed treatment with exenatide improved ALT and steatosis, but had no benefit on histology [125,126].”
BackgroundZhang, N., Tao, J., Gao, L., Bi, Y., Li, P., Wang, H., Zhu, D., & Feng, W. (2020) · BioMed Research International · doi:10.1155/2020/2947549 · Cited by 31
Savvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30
“[28] Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, et al.”
BackgroundThe cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
McCarty, M. F., & DiNicolantonio, J. J. (2014) · Open Heart · doi:10.1136/openhrt-2014-000103 · Cited by 34
Park, K.-A., Jin, Z. H., Lee, J. Y., An, H. S., Choi, E. B., Kim, K. E., Shin, H. J., Jeong, E. A., Min, K. A., Shin, M. C., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020159 · Cited by 30
“Further, ExA-trea ed mice exhibited reduced liver damage, as asse sed by NAFLD activity scores (Figure 4F), compared with untreated mice.”
BackgroundInfluentialVedtofte, L., Bahne, E., Foghsgaard, S., Bagger, J. I., Andreasen, C., Strandberg, C., Gørtz, P. M., Holst, J. J., Grønbæk, H., Svare, J. A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103213 · Cited by 29
“This is in accordance with other studies using GLP-1RAs showing either unaltered or improvements of elevated liver enzyme levels [13,15,16,20,22,23].”
ResultTarget Sestrin2 to rescue the damaged organ: mechanistic insight into its function
Ala, M., & Eftekhar, S. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8790369 · Cited by 27
“Previously, it was shown that glucagon-like peptide 1 (GLP1) agonists improved hepatic steatosis [130].”
BackgroundThe Impact of Incretin-Based Medications on Lipid Metabolism
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1815178 · Cited by 33
“Lipogenesis and lipolysis Reduces lipogenesis mainly thru an AMPK-dependent pathway [57–61, 63, 74] [63, 70, 107, 108]”
BackgroundYin, T.-T., Bi, Y., Li, P., Shen, S.-M., Wang, W.-M., Jiang, C., Gao, C.-X., Wang, Y., Gao, L.-J., Zhu, D.-L., et al. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0295-6 · Cited by 26
Bariatric surgery and nonalcoholic fatty liver disease
Bower, G., Athanasiou, T., Martínez-Isla, A., Harling, L., Li, J. V., Holmes, E. C., Efthimiou, E., Darzi, A. W., & Ashrafian, H. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000375 · Cited by 30
Linagliptin: from bench to bedside
Doupis, J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s59523 · Cited by 26
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children
Hecht, L., & Weiss, R. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0448-y · Cited by 27
Fang, T., Huang, S., Chen, Y., Chen, Z., Chen, J., & Hu, W. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1240-4936 · Cited by 25
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 31
Self-citationGuo, J., Cai, L., Yang, C., Li, B., Wei, J., Lin, Y., Ye, P., Hu, G., & Li, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8919 · Cited by 28
“Subsequently, an increasing number of studies have shown the protective role of liraglutide in the livers of diabetic and obesity patients (25,26).”
BackgroundJung, C., & Mok, J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.18 · Cited by 23
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020) · Diabetic Medicine · doi:10.1111/dme.14356 · Cited by 21
Self-citationEffect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Nowrouzi‐Sohrabi, P., Rezaei, S., Jalali, M., Ashourpour, M., Ahmadipour, A., Keshavarz, P., & Akbari, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173823 · Cited by 24
Yen, F., Hsu, C., Wei, J. C., Hou, M., & Hwu, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.839456 · Cited by 23
“Two studies have demonstrated that the use of GLP-1 receptor agonists in patients with NAFLD and T2D could reduce intrahepatic fat content (72, 73).”
BackgroundClinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 29
Dhanesha, N., Joharapurkar, A. A., Shah, G. B., Kshirsagar, S. G., PATEL, V. G., Patel, K., Bahekar, R. H., & Jain, M. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.015 · Cited by 21
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes
Cernea, S., Cahn, A., & Raz, I. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1300059 · Cited by 24
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
The role of MRI in understanding the underlying mechanisms in obesity associated diseases
Mitra, S. D., Fernández-del-Valle, M., & Hill, J. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.008 · Cited by 24
Rashid, Z., Woldesenbet, S., Khalil, M., Iyer, S., Khan, M. M. M., Altaf, A., Munir, M. M., Catalano, G., Mumtaz, K., & Pawlik, T. M. (2024) · Liver International · doi:10.1111/liv.16132 · Cited by 25
Kalra, S., Mithal, A., Zargar, A. H., Sethi, B. K., Dharmalingam, M., Ghosh, S. K., & Sen, R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.63 · Cited by 27
“The pleiotropic effect of SGLT2is and GLP-1 agonists can facilitate weight management, particularly by reducing visceral fat.(47,48) SGLT2is and GLP-1 agonists minimize weight gain when added to metformin and/or sulfonylurea, and the clinically meaningful body weight reductions can further contribute reduced HbA1c and…”
BackgroundRajeev, S. P., Sprung, V. S., Roberts, C. A., Harrold, J. A., Halford, J. C. G., Stančák, A., Boyland, E. J., Kemp, G. J., Cuthbertson, D. J., & Wilding, J. P. H. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013539 · Cited by 20
“Proton magnetic resonance spectroscopy of the liver will be performed as previously described.(11) Three voxels of interest will be identified in the liver standard sites avoiding ducts and vasculature.”
InfluentialSelf-citationDíaz, E. G., Guagnozzi, D., Gutiérrez, V., Mendoza, C., Maza, C., Larrañaga, Y., Perdomo, D., Godoy, T., & Taleb, G. (2016) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2016.05.008 · Cited by 20
Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status
Sprung, V. S., Davies, K. A. B., Norman, J. A., Thompson, A., Mitchell, K. L., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0098 · Cited by 22
Self-citationSi, M. W., Yang, M., & Fu, X. (2015) · Genetics and Molecular Research · doi:10.4238/2015.august.14.19 · Cited by 19
Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
Teshome, G., Ambachew, S., Fasil, A., & Abebe, M. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265631 · Cited by 20
Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK
Hurtado-Carneiro, V., Dongil, P., Pérez-García, A., Álvarez, E., & Sanz, C. (2021) · Antioxidants · doi:10.3390/antiox10122028 · Cited by 20
“Likewise, exendin-4 is reported to reduce liver fat in obese type 2 diabetic patients [92].”
BackgroundDobbie, L. J., Kassab, M., Davison, A., Grace, P., Cuthbertson, D. J., & Hydes, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245755 · Cited by 18
“One study reported GLP-1 agonists significantly reduce liver fat (relative reduction 42%) [49].”
BackgroundSelf-citationMittag‐Roussou, V., Wagenpfeil, S., Lammert, F., & Stokes, C. S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.131 · Cited by 17
“ALT (U/L) 28 (22-43) 29 (22-44) 25 (20-32) 29 (20-41) .”
Short-Term Physical Inactivity Induces Endothelial Dysfunction
Davies, K. A. B., Norman, J. A., Thompson, A., Mitchell, K. L., Harrold, J. A., Halford, J. C. G., Wilding, J. P. H., Kemp, G. J., Cuthbertson, D. J., & Sprung, V. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.659834 · Cited by 24
Self-citationOkubo, H., Kushiyama, A., Nakatsu, Y., Yamamotoya, T., Matsunaga, Y., Fujishiro, M., Sakoda, H., Ohno, H., Yoneda, M., & Asano, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103064 · Cited by 23
Fan, S., Shi, X., Yao, J., Zhong, M., & Feng, P. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.6392/2019 · Cited by 20
Chen, W., Ng, H.-J., Jao, A.-T., Wu, S., & Soong, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112407 · Cited by 21
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Rashied, R. M. H., Abdelfattah, M. A. O., El-Beshbishy, H. A., El-Shazly, A. M., Mahmoud, M. F., & Sobeh, M. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103822 · Cited by 16
Zhao, Y. M., Zhao, W., Bu, H., Toshiyoshi, M., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000032892 · Cited by 17
“It prevents the damage of hepatocyte lipid accumulation by reducing hepatocyte glucose, improving hepatic fibrosis and losing body weight.[53] Adverse effects (AEs) of liraglutide are mainly in gastrointestinal tract.”
BackgroundNjei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · Cureus · doi:10.7759/cureus.71366 · Cited by 30
“Various mechanisms in which this effect occurs have been reported in the literature [58,64,65], including evidence that shows the involvement of SIRT1 mediating the effect of exenatide on ameliorating hepatic steatosis [66].”
BackgroundTsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Saleem, M., Fareed, M. M., Saani, M. S. A., & Shityakov, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222837 · Cited by 20
“…glucose-lowering medications and weight loss medications, as some of the newer glucose-lowering drugs also induce weight loss, such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (Cuthbertson et al., 2012; Garvey et al., 2014).”
BackgroundDíaz, E. G., Guagnozzi, D., Gutiérrez, V., Mendoza, C., Maza, C., Larrañaga, Y., Perdomo, D., Godoy, T., & Taleb, G. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2016.01.006 · Cited by 18
Ionut, V., Castro, A. V. B., Woolcott, O. O., Stefanovski, D., Iyer, M. S., Broussard, J. L., Burch, M., Elazary, R., Kolka, C. M., Mkrtchyan, H., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2014 · Cited by 13
“Given that chronic exenatide has been shown to decrease liver steatosis (4), improve -cell function (3), and decrease body weight in type 2 diabetic patients (16), it might be of interest to investigate in future studies whether portal GLP-1 receptors are involved in mediating these changes.”
BackgroundKaji, N., Takagi, Y., Matsuda, S., Takahashi, A., Fujio, S., & Asai, F. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12106 · Cited by 13
Wernicke, C., Pohrt, A., Pletsch‐Borba, L., Apostolopoulou, K., Hornemann, S., Meyer, N. M. T., Machann, J., Gerbracht, C., Tacke, F., Pfeiffer, A. F. H., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.01.010 · Cited by 18
Blaslov, K., Zibar, K., Bulum, T., & Duvnjak, L. S. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.013 · Cited by 14
Shiomi, M., Tanaka, Y., Takada, T., & Otori, K. (2020) · JGH Open · doi:10.1002/jgh3.12384 · Cited by 13
Sawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
“Despite attempts to minimize bias through a systematic and comprehensive search strategy, unpublished or negative studies may have been overlooked.”
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
“3) [110].”
Yoo, J. H., Cho, I.-J., Jeong, I., Ahn, K. J., Chung, H. Y., & Hwang, Y. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.032 · Cited by 12
“However, the precise mechanisms by which GLP-1 contributes to NAFLD and ER stress signaling have not been fully elucidated.”
BackgroundInfluentialXiao, R., Wang, R., Shusen, L., Kang, X., Ren, Y., Sun, E., Wang, C., He, J., & Zhan, J. (2022) · Journal of Food Quality · doi:10.1155/2022/8586843 · Cited by 13
“Many reports have verified the important role of GLP-1 in glucose homeostasis and insulin sensitivity [36, 37], inferring that the combination of LC-37 and IMO or combination of MN1.”
BackgroundKuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 13
Application of butyric acid as a feed additive for improving quail performance and health
Abdeldayem, F. A., Lestingi, A., Aboul-Ela, S., Alagawany, M. M., Ismail, T. A., Mostafa, N. G., & El-Shall, N. A. (2024) · Poultry Science · doi:10.1016/j.psj.2024.104109 · Cited by 12
“Activation of GLP-1 has been demonstrated to improve hepatic steatosis, lower tri-glyceride ( TG ) content, and lower AST and ALT levels (Cuthbertson et al., 2012; Trevaskis et al., 2012).”
BackgroundMahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 15
Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis
Perry, R. J. (2019) · Obesity · doi:10.1002/oby.22559 · Cited by 10
“betes largely because of their function as insulin secretagogues, have shown additional benefit to reduce appetite and thus food intake, leading to modest weight loss and improvement in steatosis (7).”
BackgroundTratamiento actual de la enfermedad por hígado graso no alcohólico
Moctezuma‐Velázquez, C. (2018) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2017.10.003 · Cited by 23
Cuthbertson, D. J., Irwin, A., Sprung, V. S., Jones, H., Pugh, C. J. A., Daousi, C., Adams, V. L., Bimson, W. E., Shojaee‐Moradie, F., Richardson, P., et al. (2014) · Clinical Science · doi:10.1042/cs20130404 · Cited by 11
Self-citationNAFLD and cardiovascular disease
Martins, E., & Oliveira, A. B. F. D. (2018) · Porto Biomedical Journal · doi:10.1016/j.pbj.0000000000000002 · Cited by 9
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
“, 2012 [47] United Kingdom 25 19/6 Exenatide 5 μg BID/4 weeks, then 10 μg BID/20 weeks Or Liraglutide 0.”
BackgroundInfluentialItoh, A., Irie, J., Tagawa, H., Kusumoto, Y., Kato, M., Kobayashi, N., Tanaka, K., Kikuchi, R., Fujita, M., Nakajima, Y., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.013 · Cited by 13
Jia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Azagury, D. E., Alimi, Y., & Prindeze, N. J. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12086-5 · Cited by 13
Naftalin, R. J. (2016) · F1000Research · doi:10.12688/f1000research.8299.1 · Cited by 9
Current treatment for non-alcoholic fatty liver disease
Moctezuma‐Velázquez, C. (2018) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.05.014 · Cited by 15
“A study with a beforeand-after design on patients with MRS-determined steatosis that received liraglutide/exenatide showed improvement in steatosis as well as a gradient between the improvement obtained and baseline levels of steatosis.(28) The more recently published LEAN study is a CCT that randomized 26 patients, t…”
Malin Nylander, S. F. (2015) · Journal of Obesity & Weight Loss Therapy · doi:10.4172/2165-7904.1000254 · Cited by 7
“The anticipated clinical relevant difference of 6% is in accordance with a previous study reporting an absolute reduction in liver fat of 6% measured by MRI spectroscopy after 6 months treatment with GLP-1 analogue in 25 patients with [23].”
ResultYi, Y., Qin, S., Ding, S., & Fang, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144044 · Cited by 8
Li, C., Zhao, L., Zhou, X., Wu, H., & Zhao, J. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1433-2 · Cited by 8
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Hanna, S., Sethiadi, J., Ali, Q., & Sinha, S. (2025) · Cancers · doi:10.3390/cancers17162600 · Cited by 7
“These proposed mechanisms may explain how exenatide and liraglutide were found to reduce intrahepatic lipid in obese patients with hepatic stenosis in a manner not significantly correlated with reduction in total body weight, even in the absence of classical GLP-1R expression in hepatocytes [46].”
Iorra, F. D. Q., Jayakar, T., Yee, M. S., Thursz, M. R., Schaan, B. D., & Manousou, P. (2026) · Liver International · doi:10.1111/liv.70643 · Cited by 9
Salvatore, M., Zhang, B., Tang, H., Lu, Y., Zhang, D., Zhou, T., Lu, Y., Amaro, A., Ritchie, M. D., & Chen, Y. (2025) · medRxiv · doi:10.1101/2025.06.03.25328908 · Cited by 4
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
Wibawa, I. D. N., Mariadi, I. K., Somayana, G., Kumbara, C. I. Y. K., & Sindhughosa, D. A. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.549 · Cited by 4
Oshaghi, E. A. (2017) · Avicenna Journal of Medical Biochemistry · doi:10.15171/ajmb.2017.10 · Cited by 3
A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
Junker, A. E., Gluud, L. L., Pedersen, J., Langhoff, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Case Reports in Gastroenterology · doi:10.1159/000369968 · Cited by 4
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Dawood, A. A., Elghobashy, Y., & Elgamal, A. (2018) · The Egyptian Journal of Internal Medicine · doi:10.4103/ejim.ejim_34_17 · Cited by 2
Bernsmeier, C., Meyer‐Gerspach, A. C., Blaser, L. S., Jeker, L., Steinert, R. E., Heim, M. H., & Beglinger, C. (2013) · Journal of Hepatology · doi:10.1016/s0168-8278(13)61317-3 · Cited by 2
Traitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques
Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30166-9 · Cited by 2
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
Brodosi, L., Musio, A., Barbanti, F. A., Mita, D., Marchesini, G., & Petroni, M. L. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.88 · Cited by 2
“Cuthbertson et al.([62]) reported a 42% median reduction of intracellular fat content (P < 0.”
BackgroundInfluentialShinozaki, S., Tahara, T., Miura, K., Lefor, A. K., & Yamamoto, H. (2023) · Life · doi:10.3390/life13061327 · Cited by 6
“In addition, pemafibrate did not reduce total liver fat volume compared to that of the control group evaluated by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) [22].”
BackgroundInfluentialAspectos relevantes de la enfermedad por hígado graso no alcohólico
Hernández-Osorio, I. C., & Luján-Ramos, M. A. (2021) · Hepatología · doi:10.52784/27112330.137 · Cited by 3
Kahal, H. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 2
Das, S., Ravi, H., Babu, A., Banerjee, M., Ramasubbu, K., Sivaraman, D., Rajeswari, V. D., Venkatraman, G., & Ramanathan, G. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.017 · Cited by 1
Brown, E. E., Bilson, J., Alam, U., Goff, L. M., Kemp, G. J., Pfeiffer, A. F. H., Weickert, M. O., Umpleby, A. M., Byrne, C. D., & Cuthbertson, D. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112997 · Cited by 2
Self-citation
Metadata
- Authors
- Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., Pirmohamed, M., & Kemp, G. J.
- Affiliations
- University of Liverpool (GB)
- Aintree University Hospital (GB)
- Royal Liverpool University Hospital (GB)
- Countess of Chester Hospital (GB)
- Imperial College London (GB)
- Corresponding author
- Cuthbertson, Daniel J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-06
- Volume
- 7
- Issue
- 12
- Pages
- e50117
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3516516
- OpenAlex
- W2041468536
- Cited by
- 226
- References
- 37
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 9 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 22 · 2019: 12 · 2018: 19 · 2017: 14 · 2016: 22 · 2015: 18 · 2014: 35 · 2013: 13
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- WestminsterResearch (University of Westminster) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, non-alcoholic fatty liver disease, intrahepatic lipid, hepatic steatosis, glycemic control, HbA1c, exenatide, liraglutide, visceral adipose tissue, subcutaneous adipose tissue, weight loss
- MeSH terms
- Liraglutide, Exenatide, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Obesity, Peptides, Prospective Studies, Venoms, Weight Loss, Body Mass Index, Adiposity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.